FDA cracks down on supplements containing DMBA

The 14 warning letters sent by the agency address 17 products that contain the ingredient.

The FDA issued warning letters to 14 companies regarding a total of 17 products for which the product labeling identifies DMBA as a dietary ingredient.

The agency considers these products to be adulterated because they are labeled as containing a new dietary ingredient, DMBA, and because they have not satisfied the conditions to include DMBA as a dietary ingredient.

Under existing law, including the Dietary Supplement Health and Education Act passed by Congress in 1994, the FDA can take action to remove products from the market, but the agency must first establish that such products are adulterated or misbranded.

The warning letters were sent to the following companies, with the products impacted listed next to them.

DSEO LLC (Products: HybriLean and PREAMP)

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026
Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground